Article Sidebar
Published:
Dec 14, 2016Article Details
Copyright remains in the Author’s name. The work is licensed under a Creative Commons Attribution - Noncommercial Works License. Authors are required to complete and sign an Author Agreement form that outlines Author and Publisher rights and terms of publication. The Agreement form should be uploaded along with other submissions files and any submission will be considered incomplete without it [forthcoming].
Material submitted for publication in the SAMJ is accepted provided it has not been published or submitted for publication elsewhere. Please inform the editorial team if the main findings of your paper have been presented at a conference and published in abstract form, to avoid copyright infringement. The SAMJ does not hold itself responsible for statements made by the authors.
Previously published images
If an image/figure has been previously published, permission to reproduce or alter it must be obtained by the authors from the original publisher and the figure legend must give full credit to the original source. This credit should be accompanied by a letter indicating that permission to reproduce the image has been granted to the author/s. This letter should be uploaded as a supplementary file during submission.
Main Article Content
Cyclosporin in steroidresistant nephrotic syndrome
Abstract
Cyclosporin A (CyA) has recently been shown to be effective in frequently relapsing, steroid-resistant or steroid-dependent childhood nephrotic syndrome (NS). Wider acceptance has been hindered by considerations of cost, toxicity and drug-dependent maintenance of remission. Black children in Africa with NS are mainly steroid-unresponsive and alternative therapies therefore need to be assessed.
We report on 8 of 11 children who completed at least 24 weeks of CyA therapy; 6 (2 with membranous nephropathy (MEM) and 4 with focal glomerulosclerosis) showed no improvement, while 2, both with MEM, achieved remission while on CyA therapy and remained in remission for 1 and 3,5 years, respectively, after cessation of therapy. This may have been the natural course of the disease. Of the children who were unresponsive to CyA, 3 died in renal failure 8 - 30 months after cessation of CyA therapy, 1 had a rising creatinine value when last seen, and 2 were lost to follow-up. CyA trough levels varied between 180 and 875 ng/ml and peak levels between 563 and 1 950 ng/ml. Of 5 repeat renal biopsies, 3 were performed at the end of 24 weeks of treatment and revealed no evidence of CyA toxicity. Two biopsies revealed chronic CyA toxicity. CyA should therefore be used with caution at lower dosages and monitored at currently accepted lower trough levels in children with NS in Africa.
